Orphazyme co-founder becomes board chair at biotech startup

Anders Hinsby will sit at the head of the table at board meetings for Pephexia Therapeutics.
Anders Hinsby, CEO of Muna Therapeutics and chairman of the board at Pephexia Therapeutics. | Photo: Muna Therapeutics / PR
Anders Hinsby, CEO of Muna Therapeutics and chairman of the board at Pephexia Therapeutics. | Photo: Muna Therapeutics / PR
by christian bundgaard, translated by catherine brett

In 2019, Anders Hinsby left his role as CEO of Orphazyme, a company he helped to establish back in 2010.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading